Predictors of infliximab-induced deep remission in treatment-na ïve patients with isolated small bowel Crohn's disease

CONCLUSIONS: In treatment-naïve patients with isolated small bowel CD, a moderate-to-severe endoscopic disease and the presence of fibrofatty proliferation at baseline reduce the possibility of infliximab-induced deep remission. Patients with such risk factors may need more aggressive treatment at the beginning of induction therapy to promote deep remission at an early stage.PMID:34461786 | DOI:10.1080/00365521.2021.1971759

Source: Scandinavian Journal of Gastroenterology - August 31, 2021 Category: Gastroenterology Authors: Ze-Min Han Bing-Xia Chen Qian Zhou Hong-Bin Liu Pei-Chun Xu Fa-Chao Zhi Source Type: research